Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors

被引：0
|
作者：
Wang, X.
Syed, S.
Masson, E.
Walters, I. B.
Roy, A.
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Wallingford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3095
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer
    Pena-Cabia, Silvia
    Royuela Vicente, Ana
    Ramos Diaz, Ruth
    Gutierrez Nicolas, Fernando
    Penalver Vera, Angela
    Siso Garcia, Isabel
    Hitt Sabag, Ricardo
    Garcia Lacalle, Concepcion
    Pena-Cabia, Ana
    Iglesias-Peinado, Irene
    Garcia Diaz, Benito
    Lopez-Martin, Ana
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 141
  • [42] Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors
    Francois Mercier
    Nassim Djebli
    Mario González-Sales
    Felix Jaminion
    Georgina Meneses-Lorente
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 363 - 372
  • [43] Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors
    Li, Yan
    Kassir, Nastya
    Chen, Nianhang
    Wang, Xiaomin
    Palmisano, Maria
    Zhou, Simon
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (02): : 115 - 130
  • [44] Tepotinib Exposure-Response Analyses of Safety and Efficacy in Patients with Solid Tumors
    Xiong, W.
    Hietala, S.
    Nyberg, J.
    Papasouliotis, O.
    Anziano, R.
    Berghoff, K.
    Johne, A.
    Girard, P.
    Strotmann, R.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [45] Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
    He, Jimmy
    Jackson, Christopher G. C. A.
    Deva, Sanjeev
    Hung, Tak
    Clarke, Katriona
    Segelov, Eva
    Chao, Tsu-Yi
    Dai, Ming-Shen
    Yeh, Hsien-Tang
    Ma, Wen Wee
    Kramer, Douglas
    Chan, Wing-Kai
    Kwan, Rudolf
    Cutler, David
    Zhi, Jay
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (07): : 867 - 879
  • [46] Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
    Cohn, A. Lee
    Yoshino, T.
    Obermannova, R.
    Bodoky, G.
    Prausova, J.
    Garcia-Carbonero, R.
    Ciuleanu, T. Eliade
    Garcia-Alfonso, P.
    Portnoy, D. C.
    Van Cutsem, E.
    Yamazaki, K.
    Clingan, P. R.
    Polikoff, J.
    Lonardi, S.
    Gao, L.
    Yang, L.
    Chang, S. C.
    Ferry, D.
    Nasroulah, F.
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S372 - S372
  • [47] Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
    Lonardi, S.
    Cohn, A. L.
    Yoshino, T.
    Obermannova, R.
    Bodoky, G.
    Prausova, J.
    Garcia-Carbonero, R.
    Ciuleanu, T.
    Garcia-Alfonso, P.
    Portnoy, D. C.
    Van Cutsem, E.
    Yamazaki, K.
    Clingan, P. R.
    Polikoff, J.
    Gao, L.
    Yang, L.
    Chang, S.
    Ferry, D.
    Nasroulah, F.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
    Dosne, Anne-Gaelle
    Valade, Elodie
    Goeyvaerts, Nele
    De Porre, Peter
    Avadhani, Anjali
    O'Hagan, Anne
    Li, Lilian Y.
    Ouellet, Daniele
    Ruixo, Juan Jose Perez
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (02) : 151 - 164
  • [49] POPULATION PHARMACOKINETICS (POPPK) MODELING AND EXPOSURE-RESPONSE (ER) RELATIONSHIP ANALYSES OF CEMIPLIMAB (CEMI) IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER (R/M CC).
    Nguyen, J.
    Epling, D.
    Dolphin, N.
    Paccaly, A.
    Davis, J.
    Al-Huniti, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S38 - S38
  • [50] NIVOLUMAB EXPOSURE-RESPONSE (E-R) ANALYSIS FOR CLINICAL DEVELOPMENT OF NIVOLUMAB IN ADVANCED REFRACTORY SQUAMOUS NON-SMALL CELL LUNG CANCER.
    Feng, Y.
    Wang, X.
    Agrawal, S.
    Lestini, B.
    Park, J.
    Roy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S7 - S7
12345